

Search > Results > Results

483 results from Web of Science Core Collection for:

"pulmonary hypertension" AND treprostinil (All Fields)

Analyze Results Citation Report Create Alert

Copy query link

Publications You may also like...

Back to all filters

Refine by Publication Years

Search for Publication Years

Select all

Date

<input type="checkbox"/> 2022	1	<input type="checkbox"/> 2014	26	<input type="checkbox"/> 2006	10
<input type="checkbox"/> 2021	36	<input type="checkbox"/> 2013	31	<input type="checkbox"/> 2005	15
<input type="checkbox"/> 2020	44	<input type="checkbox"/> 2012	16	<input type="checkbox"/> 2004	12
<input type="checkbox"/> 2019	41	<input type="checkbox"/> 2011	21	<input type="checkbox"/> 2003	11
<input type="checkbox"/> 2018	37	<input type="checkbox"/> 2010	20	<input type="checkbox"/> 2002	6
<input type="checkbox"/> 2017	42	<input type="checkbox"/> 2009	15	<input type="checkbox"/> 2001	1
<input type="checkbox"/> 2016	31	<input type="checkbox"/> 2008	19		
<input type="checkbox"/> 2015	35	<input type="checkbox"/> 2007	13		

Cancel Exclude Refine



Search > Results > Results

55 results from Web of Science Core Collection for:

Q "pulmonary hypertension" AND treprostinil (All Fields)

Analyze Results Citation Report Create Alert

Refined By: Publication Years: 2001 or 2002 or 2003 or 2004 or 2005 or 2006 X Clear all

Copy query link

Publications You may also like...

Refine results

Search within results for...

Quick Filters

- Review Articles 12
- Open Access 10

Publication Years

- 2006 10
- 2005 15
- 2004 12
- 2003 11
- 2002 6

See all >

Document Types

- Articles 32
- Review Articles 12
- Meeting Abstracts 8
- Editorial Materials 2
- Letters 1

See all >

Web of Science Categories

- Cardiac Cardiovascular Systems 18
- Respiratory System 15
- Pharmacology Pharmacy 12
- Critical Care Medicine 9
- Medicine General Internal 7

See all >

Authors

- Barst RJ 7
- Seeger W 7
- Enke B 6
- Olschewski H 6
- Reichenberger F 6

See all >

Affiliations

- COLUMBIA UNIVERSITY 8
- UNITED THERAPEUTICS CORPORATION 8
- HOSPITAL UNIVERSITARIO 12 DE OCTUBRE 6
- UNIVERSITY OF MICHIGAN 4
- UNIVERSITY OF MICHIGAN SYSTEM 4

See all >

Publication Titles

- CHEST 5
- EUROPEAN HEART JOURNAL 4
- AMERICAN JOURNAL OF RESPIRATORY AND... 3
- JOURNAL OF CARDIOVASCULAR PHARMAC... 3
- EUROPEAN RESPIRATORY JOURNAL 2

See all >

0/55 Add To Marked List Export Relevance 1 of 2

1 Treatment of HIV-associated pulmonary hypertension with treprostinil
 Cea-Calvo, J; Subias, PE; (...); de la Calzada, CS
 Apr 2003 | REVISTA ESPANOLA DE CARDIOLOGIA 56 (4), pp.421-425
 Background and objective. The treatment of pulmonary hypertension associated with infection by human immunodeficiency virus has not been well defined. Treprostinil is a prostacyclin analogue that has recently been shown to be useful for the treatment of pulmonary hypertension, whether primary, secondary to congenital heart disease, or as ... Show more
 Full Text at Publisher ***
 Citations: 31, References: 13, Related records

2 Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension
 Subias, PE; Cea-Calvo, J; (...); de la Calzada, CS
 Aug 2003 | REVISTA ESPANOLA DE CARDIOLOGIA 56 (8), pp.818-821
 Treatment of arterial pulmonary hypertension with epoprostenol (intravenous prostacyclin) improves survival and quality of life, but the need for an implanted central venous catheter is associated with frequent complications, that often (as in the case of infection or dislodgment) are serious and require catheter replacement. Treprostinil is a prostacycl ... Show more
 Full Text at Publisher Full Text at Publisher ***
 Citations: 3, References: 9, Related records

3 Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension
 Lang, J; Gomez-Sanchez, M; (...); Yachery, JL
 Jun 2006 | CHEST 129 (6), pp.1636-1643
 Study objectives: The aim of this long-term multicenter analysis was to investigate whether subcutaneously infused treprostinil could provide sustained improvements of exercise capacity and survival benefits in patients with pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Subc ... Show more
 Full Text at Publisher ***
 Citations: 155, References: 25, Related records

4 Sildenafil as a substitute for subcutaneous prostacyclin in pulmonary hypertension
 Cea-Calvo, J; Subias, PE; (...); de la Calzada, CS
 Oct 2003 | ARCHIVOS DE BRONCONFUMOLOGIA 39 (10), pp.476-477
 Subcutaneous prostacyclin (treprostinil) is an effective short-term treatment for pulmonary hypertension. The most frequently described adverse effect-pain in the area of injection-rarely requires that treatment be withdrawn. Sildenafil is a selective fosfodiesterase-5 inhibitor with pulmonary vasodilating effects. We describe the use of sildenafil as a ... Show more
 Full Text at Publisher ***
 Citations: 2, References: 9, Related records

5 Efficacy and safety of treprostinil: An Epoprostenol analog for primary pulmonary hypertension
 McLaughlin, VJ; Gaine, SP; (...); Rich, S
 Feb 2003 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 41 (2), pp.293-299
 Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires intravenous infusion and is associated with adverse effects. The objective of this study was to evaluate the effects of an epoprostenol analog, treprostinil, for management of pulmonary hypertension. Ten tertiary care ac ... Show more
 Full Text at Publisher ***
 Citations: 166, References: 9, Related records

6 Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
 Gombert-Maitland, M; Tapson, VE; (...); Barst, RJ
 Dec 15 2005 | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 172 (12), pp.1586-1589
 Rationale: Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension. The prostacyclin analog treprostinil is also efficacious by subcutaneous infusion, is easier to administer, and has a longer half-life. With the demonstration of bioequivalence between subcutaneous and intravenous treprostinil, it ... Show more
 Full Text at Publisher ***
 Citations: 157, References: 13, Related records

7 Treprostinil for the treatment of severe digital necrosis in systemic sclerosis
 Engel, G and Rockson, SG
 2005 | VASCULAR MEDICINE 10 (1), pp.29-32
 We report a case of severe digital ulcerations associated with systemic sclerosis, successfully treated with treprostinil (Remodulin(R)). There was improvement within days of the treatment initiation; complete healing was accomplished after 16 weeks of therapy. Patients with systemic sclerosis and peripheral small vessel disease have limited th ... Show more
 Free Full Text From Publisher ***
 Citations: 8, References: 20, Related records



- Publishers** New ▼
- Elsevier 12
 - Lippincott Williams & Wilkins 7
 - Wiley 7
 - Amer Thoracic Soc 4
 - Amer Coll Chest Physicians 3
- [See all >](#)
-
- Funding Agencies** ▲
-
- Open Access** ① ▲
-
- Editors** ▲
-
- Group Authors** ▲
-
- Research Areas** ▲
-
- Countries/Regions** ▲
-
- Languages** ▲
-
- Conference Titles** ▲
-
- Book Series Titles** ▲
-
- Web of Science Index** ▲
-
- For more options, use [Analyze Results](#)

8 **Current and emerging therapy for primary pulmonary hypertension** 11 Citations

[Pass, SE](#) and [Dusing, ML](#)
 Sep 2002 | [ANNALS OF PHARMACOTHERAPY](#) 36 (9) , pp.1414-1423

OBJECTIVE: To review the epidemiology, pathophysiology, clinical symptoms, and diagnostic workup of primary pulmonary hypertension (PPH) and to discuss the available data on the current and emerging therapies being used to treat this disorder.
DATA SOURCES: Primary and review articles were identified with a MEDLINE search (1966-December: ... [Show more](#)

[Full Text at Publisher](#) *** [Related records](#)

9 **Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation** 18 Citations

[Sandifer, BJ](#); [Briegleb, KL](#); (...); [Parker, RE](#)
 Dec 2005 | [JOURNAL OF APPLIED PHYSIOLOGY](#) 99 (6) , pp.2363-2368

Inhaled vasodilator therapy for pulmonary hypertension may decrease the systemic side effects commonly observed with systemic administration. Inhaled medications only reach ventilated areas of the lung, so local vasodilation may improve ventilation-perfusion matching and oxygenation. We compared the effects of intravenous vs. aerosol ... [Show more](#)

[Full Text at Publisher](#) *** [Related records](#)

10 **Treprostinil in advanced experimental pulmonary hypertension: Beneficial outcome without reversed pulmonary vascular remodeling** 11 Citations

[van Albad, ME](#); [van Veehel, B](#); (...); [Berger, REME](#)
 Nov 2006 | [JOURNAL OF CARDIOVASCULAR PHARMACOLOGY](#) 48 (5) , pp.249-254

Introduction: Beneficial effects of treprostinil, a stable prostacyclin analogue, were demonstrated in patients with pulmonary arterial hypertension (PAH). Although regression of pulmonary vascular remodeling has been suggested as therapeutic mechanism, its mode of action remains unknown. ... [Show more](#)

[Free Published Article From Repository](#) [Full Text at Publisher](#) *** [Related records](#)

11 **Favorable effects of inhaled - Treprostinil in severe pulmonary hypertension - Results from randomized controlled pilot studies** 106 Citations

[Voswinckel, B](#); [Enke, B](#); (...); [Olschewski, H](#)
 Oct 17 2006 | [JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY](#) 48 (8) , pp.1672-1681

OBJECTIVES This study sought to investigate the effects of inhaled treprostinil on pulmonary hemodynamics and gas exchange in severe pulmonary hypertension.
BACKGROUND Inhaled iloprost therapy has a proven clinical efficacy in pulmonary arterial hypertens ... [Show more](#)

[Free Full Text From Publisher](#) *** [Related records](#)

12 **Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial** 968 Citations

[Simonneau, G](#); [Barst, RJ](#); (...); [Rubin, LJ](#)
 Mar 15 2002 | [AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE](#) 165 (6) , pp.800-804

Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous prostacyclin has proven to be effective. However, this treatment requires a permanent central venous catheter with the associated risk of serious complications such as sepsis, thromboembolism, or syncope. Treprostinil, a stable prostacyclin anal ... [Show more](#)

[Full Text at Publisher](#) *** [Related records](#)

13 **Pulmonary hypertension in collagen vascular disease** 40 Citations

[Hoeger, MM](#)
 Mar 2002 | [EUROPEAN RESPIRATORY JOURNAL](#) 19 (3) , pp.571-576

Pulmonary hypertension is a serious but often overlooked complication in collagen vascular disease. The understanding of the development of pulmonary hypertension has increased substantially during the last years.
 Abnormal proliferation of pulmonary vascular cells is now being regarded as a predominant process ... [Show more](#)

[Free Full Text From Publisher](#) *** [Related records](#)

14 **Pulmonary hypertension** 33 Citations

[McLaughlin, VW](#) and [Rich, S](#)
 Oct 2004 | [CURRENT PROBLEMS IN CARDIOLOGY](#) 29 (10) , pp.575-634

Pulmonary hypertension, in its simplest sense, is elevation of the pulmonary artery pressure above normal. A multitude of diseases may increase the pulmonary artery pressure and result in right ventricular dysfunction. The treatments of pulmonary hypertension are as varied as its causes. The past decade has realized remarkable growth in knowled ... [Show more](#)

[Free Submitted Article From Repository](#) [Full Text at Publisher](#) *** [Related records](#)

15 **Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension** 70 Citations

[Gomberg-Maitland, M](#); [McLaughlin, V](#); (...); [Rich, S](#)
 Nov 1 2005 | [AMERICAN JOURNAL OF CARDIOLOGY](#) 96 (9) , pp.1334-1336

Pulmonary arterial hypertension (PAH) is characterized by abnormalities in endothelial and smooth muscle cell function. Prostacyclin released by endothelial cells is a potent vasodilator by increasing cyclic adenosine monophosphate. Sildenafil, an inhibitor of phosphodiesterase-5, increases cyclic guanosine monophosphate in the lungs, producin ... [Show more](#)

[Full Text at Publisher](#) *** [Related records](#)

16 **Comparison and validation of three measures of quality of life in patients with pulmonary hypertension** 47 Citations

[Chua, B](#); [Keogh, AM](#); (...); [O'Loughlin, A](#)
 Nov 2006 | [INTERNAL MEDICINE JOURNAL](#) 36 (11) , pp.705-710

Background: Pulmonary hypertension, when advanced, markedly limits exercise capacity, activities of daily living and quality of life (QoL). No measure of QoL has yet been validated for the assessment of pulmonary hypertension. The aim of the study was to compare the validity of the Minnesota Living with Heart Failure (MLWHF) questionnaire, the SF ... [Show more](#)

[Full Text at Publisher](#) *** [Related records](#)



- 17 **Transitioning from IV epoprostenol to subcutaneous [treprostinil](#) in pulmonary arterial hypertension**
[Vachery JL, Hill M; \(...\); Naeije R](#)
 May 2002 | [CHEST](#) 121 (5) , pp.1561-1565
 Objective: Continuous IV epoprostenol (prostacyclin) therapy improves survival and quality of life in patients with pulmonary arterial hypertension (PAH). IV epoprostenol therapy may be limited by serious complications related to the need for an implanted central venous catheter, and its chemical instability and short half-life. [Treprostinil](#) is a lon ... [Show more](#)
[Full Text at Publisher](#) ***
 Citations: 78
 References: 16
[Related records](#)
- 18 **[Treprostinil](#) therapy for [pulmonary artery hypertension](#)**
[Horn EM and Barst RJ](#)
 Nov 2002 | [EXPERT OPINION ON INVESTIGATIONAL DRUGS](#) 11 (11) , pp.1615-1622
[Pulmonary artery hypertension](#) is a life-threatening disease characterised by a pulmonary vasculopathy and progressive right ventricular failure. Major advances were made with the development of continuous intravenous epoprostenol (Flolan(TM)) as a treatment modality. Nevertheless, it is far from ideal as treatment for this disease. Subcutaneous [tre](#) ... [Show more](#)
[Full Text at Publisher](#) ***
 Citations: 10
 References: 23
[Related records](#)
- 19 **Absolute bioavailability and pharmacokinetics of [treprostinil](#) sodium administered by acute subcutaneous infusion**
[Wade M; Baker EJ; \(...\); Lai AA](#)
 Jan 2004 | [JOURNAL OF CLINICAL PHARMACOLOGY](#) 44 (1) , pp.83-88
 The objective of this study was to evaluate the absolute bioavailability and acute pharmacokinetics of [treprostinil](#) sodium administered by continuous, short-term subcutaneous infusion in normal subjects. Fifteen healthy volunteers received [treprostinil](#) via an intravenous infusion at 15 ng/kg/ min over 150 minutes, followed by a 5- to 7-day v ... [Show more](#)
[Full Text at Publisher](#) ***
 Citations: 39
 References: 12
[Related records](#)
- 20 **Effect of continuous subcutaneous [treprostinil](#) therapy on the pharmacodynamics and pharmacokinetics of warfarin**
[Wade M; Hunt TL and Lai AA](#)
 Jun 2003 | [JOURNAL OF CARDIOVASCULAR PHARMACOLOGY](#) 41 (6) , pp.908-915
[Treprostinil](#) sodium was recently approved in the United States for continuous subcutaneous infusion in the treatment of pulmonary arterial hypertension (PAH). Anticoagulation with warfarin is recommended in PAH therapy. Given the likelihood for [treprostinil](#) and warfarin coadministration, a single-blind, controlled, crossover study was conducted ... [Show more](#)
[Full Text at Publisher](#) ***
 Citations: 16
 References: 22
[Related records](#)
- 21 **Pharmacokinetics of [treprostinil](#) sodium administered by 28-day chronic continuous subcutaneous infusion**
[Wade M; Baker EJ; \(...\); Lai AA](#)
 May 2004 | [JOURNAL OF CLINICAL PHARMACOLOGY](#) 44 (5) , pp.503-509
 The objective of this study was to assess the pharmacokinetics and safety of [treprostinil](#) sodium administered as a 28-day continuous subcutaneous infusion at escalating infusion rates of 2.5 to 15 ng/kg/min in normal subjects. Fourteen healthy adult volunteers received a 28-day continuous subcutaneous infusion of [treprostinil](#) at escalating infi ... [Show more](#)
[Full Text at Publisher](#) ***
 Citations: 31
 References: 17
[Related records](#)
- 22 **Stability and preservative effectiveness of [treprostinil](#) sodium after dilution in common intravenous diluents**
[Phares KR; Weiser WE; \(...\); Wade M](#)
 May 1 2003 | [AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY](#) 60 (9) , pp.916-922
 The stability of [treprostinil](#) sodium after dilution in three common i.v. infusion vehicles was assessed. The chemical stability of [treprostinil](#) sodium was tested over a 48-hour period at 40 degreesC and 75% relative humidity after dilution in each of three diluents: sterile water for injection, 0.9% sodium chloride injection, and 5% t ... [Show more](#)
[Full Text at Publisher](#) ***
 Citations: 15
 References: 8
[Related records](#)
- 23 **Prostacyclin for [pulmonary hypertension](#) in adults**
[Paramothayan NS; Lasserson T; \(...\); Walters EH](#)
 2005 | [COCHRANE DATABASE OF SYSTEMATIC REVIEWS](#) (2)
 Background Primary [pulmonary hypertension](#) (PPH) is progressive, resulting in right ventricular failure. [Pulmonary hypertension](#) can be idiopathic or associated with other conditions. Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation, and can be given orally, subcutaneously, intravenously or inhaled via a nebuliser ... [Show more](#)
[Free Published Article From Repository](#) [Full Text at Publisher](#) ***
 Citations: 78
 References: 98
[Related records](#)
- 24 **[Treprostinil](#) (Remodulin (TM)) in connective tissue disease-associated [pulmonary hypertension](#).**
[Oudiz RJ; Schily B; \(...\); Jeffs RA](#)
 Dec 2001 | [ARTHRITIS AND RHEUMATISM](#) 44 (12) , pp.2946-2946
 ...
 Citations: 0
 References: 0
- 25 **Prostacyclin and its analogues in the treatment of [pulmonary hypertension](#)**
[Olschewski H; Rose F; \(...\); Seeger W](#)
 May 2004 | [PHARMACOLOGY & THERAPEUTICS](#) 102 (2) , pp.139-153
 Prostacyclin and its analogues (prostanoids) are potent vasodilators and possess antithrombotic and antiproliferative properties. All of these properties help to antagonize the pathological changes that take place in the
[Show more](#)
 Citations: 90
 References: 141

[Full Text at Publisher](#) ***

[Related records](#)

- 26 Transition from epoprostenol and **treprostinil** to the oral endothelin receptor antagonist bosentan in patients with **pulmonary hypertension**

37
Citations

[Suleman, N](#) and [Fross, AE](#)

99th International Conference of the American-Thoracic-Society
Sep 2004 | [CHEST](#) 126 (3), pp.808-815

13
References

Study objectives: Prior to the availability of the oral endothelin antagonist bosentan, most patients with pulmonary arterial hypertension (PAH) were treated with continuously infused prostacyclins. Many patients receiving prostacyclins would have received bosentan if it had been available at the time of their diagnosis. Noninvasive criteria (sympto ... [Show more](#)

[Full Text at Publisher](#) ***

[Related records](#)

- 27 Advances in the treatment of secondary **pulmonary hypertension**

24

[Maloney, JP](#)

Mar 2003 | [CURRENT OPINION IN PULMONARY MEDICINE](#) 9 (2), pp.139-143

Citations

Pulmonary hypertension (PH) occurs frequently in parenchymal lung disease and is usually correlated with increased mortality. Thus, the treatment of PH in patients with lung disease has been an active area of interest. Secondary **pulmonary hypertension** (SPH), whether from parenchymal lung disease or other etiologies, is more common th ... [Show more](#)

17
References

[Full Text at Publisher](#) ***

[Related records](#)

- 28 Overview of **treprostinil** sodium for the treatment of pulmonary arterial hypertension

8

[Rudev, MM](#), [Minai, OA](#) and [Arroliga, AC](#)

Mar 2004 | [DRUGS OF TODAY](#) 40 (3), pp.225-234

Citations

Pulmonary arterial hypertension is a life-threatening disorder that refers to a group of diseases characterized by an abnormal elevation of the blood pressure within the pulmonary circulation due to a vasculopathy of the pulmonary microcirculation (1). If left untreated, the overall prognosis of pulmonary arterial hypertension is poor, with a 5-year survi ... [Show more](#)

45
References

[Full Text at Publisher](#) ***

[Related records](#)

- 29 Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts

70
Citations

[Ali, Fy](#), [Egan, K](#); (-); [Mitchell, JA](#)

Feb 2006 | [AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY](#) 34 (2), pp.242-246

20

Prostacyclin and its mimetics are used therapeutically for the treatment of **pulmonary hypertension**. These drugs act via cell surface prostacyclin receptors (IP receptors); however, some of them can also activate the nuclear receptor peroxisome proliferator-activated receptor beta (PPAR beta). We examined the possibility that PPAR beta is a ther ... [Show more](#)

References

[Full Text at Publisher](#) ***

[Related records](#)

- 30 Inhaled **treprostinil** sodium (TRE) for the treatment of **pulmonary hypertension**

0

[Voswinckel, B](#), [Enke, B](#); (-); [Olschewski, H](#)

77th Scientific Meeting of the American-Heart-Association
Oct 26 2004 | [CIRCULATION](#) 110 (17), pp.295-295

References

- 31 Combining **treprostinil** and sildenafil in the treatment of **pulmonary hypertension**

2

[Chua, R](#) and [Keogh, A](#)

Nov 2005 | [INTERNAL MEDICINE JOURNAL](#) 35 (11), pp.684-U3

Citations

[Full Text at Publisher](#) ***

6
References

[Related records](#)

- 32 Current medical treatment of pulmonary arterial hypertension

8

[Sulica, R](#) and [Poon, M](#)

Mar 2004 | [MOUNT SINAI JOURNAL OF MEDICINE](#) 71 (2), pp.103-114

Citations

Primary **pulmonary hypertension** is a rare disease of the pulmonary vasculature manifested by dyspnea on exertion, syncope, and signs and symptoms of right heart failure. In the absence of adequate treatment, primary **pulmonary hypertension** has a grave prognosis, with a median survival of 2.8 years. Pulmonary arterial hypertension develops in as: ... [Show more](#)

83
References

[Related records](#)

- 33 Combination of oral sildenafil and inhaled **treprostinil** in severe **pulmonary hypertension**

0

[Voswinckel, B](#), [Enke, B](#); (-); [Olschewski, H](#)

27th Congress of the European-Society-of-Cardiology
Sep 2005 | [EUROPEAN HEART JOURNAL](#) 26, pp.113-114

References

- 34 Inhaled **treprostinil** is a potent pulmonary vasodilator in severe **pulmonary hypertension**

1

[Voswinckel, B](#), [Kobstall, MG](#); (-); [Olschewski, H](#)

ESC Congress 2004
Aug-sep 2004 | [EUROPEAN HEART JOURNAL](#) 25, pp.22-22

Citation

0
References

...

- 35 The prostacyclin analogue **treprostinil** blocks NF kappa B nuclear translocation in human alveolar macrophages

[Raychaudhuri, B; Malur, A; Thomassen, MJ](#)
Sep 6 2002 | [JOURNAL OF BIOLOGICAL CHEMISTRY](#) 277 (36) , pp.33344-33348

Primary **pulmonary hypertension** (PPH) is characterized by increased pulmonary arterial pressure and vascular resistance. We and others have observed that inflammatory cytokines and infiltrates are present in the lung tissue, but the significance is uncertain. **Treprostinil** (TRE), a prostacyclin analogue with extended half-life and chemical stability, is ... [Show more](#)

[Free Full Text From Publisher](#) ...

37
Citations
32
References

[Related records](#)

- 36 Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension.

[Caneva, JO and Osses, JM](#)
2003 | [MEDICINA-BUENOS AIRES](#) 63 (3) , pp.233-236

Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is defined as a group of diseases characterised by a progressive increase of pulmonary vascular resistance leading to right ventricular failure and death. A dysregulation of prostacyclin metabolic pathways has been dem ... [Show more](#)

...

1
Citation
16
References

[Related records](#)

Find It at JH Libraries

Export

Add To Marked List

< 1 of 1 >

Inhaled treprostinil sodium (TRE) for the treatment of pulmonary hypertension

By: Voswinckel, R (Voswinckel, R); Enke, B (Enke, B); Kreckel, A (Kreckel, A); Reichenberger, F (Reichenberger, F); Krick, S (Krick, S); Gall, H (Gall, H); Gessler, T (Gessler, T); Schmehl, T (Schmehl, T); Kohstall, MG (Kohstall, MG); Grimminger, F (Grimminger, F); ...More
[View Web of Science ResearcherID and ORCID](#) (provided by Clarivate)

CIRCULATION

Volume: 110 **Issue:** 17 **Page:** 295-295 **Supplement:** S **Meeting Abstract:** 1414

Published: OCT 26 2004

Document Type: Meeting Abstract

Conference

Meeting: 77th Scientific Meeting of the American-Heart-Association

Location: New Orleans, LA

Date: NOV 07-10, 2004

Sponsor: Amer Heart Assoc

Abstract

Author Information

Addresses: Univ Hosp Giessen, Giessen, Germany

Affiliation

University Hospital of Giessen & Marburg

Categories/Classification

Research Areas: Cardiovascular System & Cardiology

+ See more data fields

Journal information

CIRCULATION

ISSN: 0009-7322

eISSN: 1524-4539

Current Publisher: LIPPINCOTT WILLIAMS & WILKINS, TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Research Areas: Cardiovascular System & Cardiology

Web of Science Categories: Cardiac & Cardiovascular Systems; Peripheral Vascular Disease

View category quartiles

Citation Network

In Web of Science Core Collection

0

Citations

Create citation alert

Cited References

0

You may also like...

Hayes, D; Tobias, JD; Whitson, BA; et al.
PULMONARY HYPERTENSION IN CYSTIC FIBROSIS IN RELATION TO OTHER LUNG DISEASES PRIOR TO LUNG TRANSPLANTION
 PEDIATRIC PULMONOLOGY

Cowburn, PJ; McArthur, JD; Cleland, JGF; et al.
 Pulmonary and systemic responses to substance P in patients with heart failure with and without pulmonary hypertension
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Bennett, J;
 Anaesthesia recommendations for Eisenmenger syndrome
ANASTHESIOLOGIE & INTENSIVMEDIZIN

Yuan, H; Wang, H; Peng, L; et al.
REGULATION OF CIRCULATING MICRORNAS IN OBSTRUCTIVE SLEEP APNEA PATIENTS WITH PULMONARY HYPERTENSION
 SLEEP

Bray, JP; Adams, DR; Adams, PS; et al.
 Sugammadex Neuromuscular Blockade Reversal Associated With Lower Postoperative Arterial Carbon Dioxide Levels After Congenital Cardiac Surgery
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA

See all

Use in Web of Science

Web of Science Usage Count

0

Last 180 Days

4

Since 2013

Learn more

This record is from:

Web of Science Core Collection

- Science Citation Index Expanded (SCI-EXPANDED)
- Conference Proceedings Citation Index - Science (CPCI-S)

Suggest a correction

If you would like to improve the quality of the data in this record, please Suggest a correction



Export

Add To Marked List

< 1 of 1 >

Inhaled treprostinil is a potent pulmonary vasodilator in severe pulmonary hypertension

By: Voswinckel, R (Voswinckel, R); Kohstall, MG (Kohstall, MG); Enke, B (Enke, B); Gessler, T (Gessler, T); Reichenberger, F (Reichenberger, F); Ghofrani, HA (Ghofrani, HA); Seeger, W (Seeger, W); Olschewski, H (Olschewski, H)

[View Web of Science ResearcherID and ORCID](#) (provided by Clarivate)

EUROPEAN HEART JOURNAL

Volume: 25 Page: 22-22 Supplement: S

Published: AUG-SEP 2004

Document Type: Meeting Abstract

Conference

Meeting: ESC Congress 2004

Location: Munich, GERMANY

Date: AUG 28-SEP 01, 2004

Sponsor: ESC

Author Information

Addresses: Med Clin 2, Dept Internal Med, Giessen, Germany

Categories/Classification

Research Areas: Cardiovascular System & Cardiology

+ See more data fields

Journal information

EUROPEAN HEART JOURNAL

ISSN: 0195-668X

Current Publisher: OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND

Research Areas: Cardiovascular System & Cardiology

Web of Science Categories: Cardiac & Cardiovascular Systems

View category quartiles

Citation Network

In Web of Science Core Collection

1

Citation

Create citation alert

All Citations

1 In All Databases

+ See more citations

Cited References

0

You may also like...

Voswinckel, R; van Dijk, J; Rubin, LJ; et al. Long Term Open Label Treatment with Inhaled Treprostinil for Pulmonary Arterial Hypertension AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Shapiro, S; Mandras, S; Nelsen, AC; et al. Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 mu g (nine breaths) four times daily PULMONARY CIRCULATION

Khan, AA; Ackerbauer, K; Tandon, R; Safety And Tolerability Of Outpatient Transition Of Parenteral And Inhaled Treprostinil To Oral Treprostinil In Patients With Pulmonary Arterial Hypertension AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Ford, H; Anderson, W; Carson, S; et al. INHALED TREPROSTINIL FOR PATIENTS AT RISK FOR ARDS CHEST

Tonelli, AR; Sahay, S; Nelsen, AC; et al. Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies PULMONARY CIRCULATION

See all

Most Recently Cited by

Ghofrani, HA; Voswinckel, R; Seeger, W; et al. Emerging therapies for the treatment of pulmonary arterial hypertension HERZ

Use in Web of Science

Web of Science Usage Count

1

Last 180 Days

[Learn more](#)

2

Since 2013

This record is from:

Web of Science Core Collection

- Conference Proceedings Citation Index - Science (CPCI-S)
- Science Citation Index Expanded (SCI-EXPANDED)

Suggest a correction

If you would like to improve the quality of the data in this record, please Suggest a correction